Pharmafile Logo

Spotlight on Saudi Arabia

August 25, 2015 | Saudi Arabia, emerging markets 

Published in eyeforpharma 20 May by Rachel Howard

What are the opportunities and challenges for pharma companies wishing to gain a foothold in this oil-rich kingdom?

Traditionally the Middle East and North Africa (MENA) region has been overlooked by pharmaceutical companies, with the region contributing only about 2% of global pharmaceutical sales in 2010. Difficult regulatory environments and political turmoil have compounded the perceived lack of attractiveness of the region as a whole.

As we reach the middle of the decade, could the tide be turning? Over the last year, I have noticed increasing industry interest in Saudi Arabia (KSA) – and with good reason given it is the fastest growing pharmaceutical market in the Middle East, experiencing double-digit growth. In this article, I will take a look at the opportunities and challenges for pharma companies wishing to gain a foothold in this oil-rich kingdom.

Background

Though vast swathes of the country are uninhabitable desert, Saudi Arabia has a population fast approaching 30 million. It is a young country, with over half of the population under 30 years of age. As it is home to the holy Islamic cities of Mecca and Medina, its population receives a seasonal boost as over two million pilgrims visit each year to perform the Hajj. It also contains about a quarter of the world’s known petroleum reserves, and oil revenues account for approximately 90 percent of the government’s income.

A key pillar of Saudi Arabia’s internal stability relative to much of the surrounding region has been the kingdom’s generous social welfare system, of which healthcare forms an important segment. Healthcare services are available free of charge not only to Saudi citizens but also to all pilgrims, regardless of their nationality. Recent decades have seen considerable improvement in both the quantity and quality of healthcare services. A Royal Decree in 2002 resulted in sizeable expansion of the primary care network. Care in the top public hospitals, such as Riyadh’s renowned King Fahad Medical City, easily rivals that of the West, with imported medical technology and state-of-the-art facilities. Medical education is also fully funded by the state, including overseas training. As a result, many physicians are trained in leading US and UK medical schools.

However, not all is rosy. Despite the country’s affluence and stated commitment to healthcare, indicators suggest Saudi Arabia’s overall healthcare performance remains mediocre compared with the West, with an infant mortality rate that is double the average and a shorter life expectancy.

Read the full article at http://www.researchpartnership.com/news/2015/05/spotlight-on-saudi-arabia/

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Research Partnership launches new patient Living with Psoriasis 2017 (EU) report

Living with Psoriasis is a study conducted amongst 615 patients in Europe. The report will consist of 30-minute online interviews with 600 patients and 15 qualitative interviews. It can be purchased...

Deep Dive – MINT: opportunities in ‘frontier’ markets?

According to British economist Jim O’Neill, MINT is the new BRIC. What is MINT? An acronym he coined for the ‘frontier’ markets of Mexico, Indonesia, Nigeria and Turkey. These are...

Webcast: Going for growth – Maximising your return on insights in Emerging Markets

Healthcare market research in emerging markets is still evolving, so finding the insights you require and then maximising the return on those insights can be challenging. Healthcare market research in emerging...

20 questions: Round 6

As it's our 20th year anniversary, we invited our employees to play our version of 20 questions - this month we asked our employees about office life in Singapore.Watch the video: https://www.researchpartnership.com/news/2017/09/20-questions-round-6/

Ageing Asia: What does this mean for the future of healthcare?

Over the last 30 years, Asia’s economic growth has resulted in improved education and healthcare across a broad base of the population. This has contributed to declining fertility and increasing...

Punching above your weight: Combining behavioural and attitudinal data to strengthen segmentations

Segmentation solutions in healthcare are experiencing a welcome comeback. But there appear to be two camps emerging - one camp are proponents of the 'behavioural' segmentation based on secondary sales,...

Qualitative segmentation validation study with backroom brainstorm exercises

Our client had an oncology product in development for the treatment of prostate cancer. The company wanted to conduct research to inform future planning, list development, advisory board creation, and...

PMRC EU, Düsseldorf 2017

We are delighted to be exhibiting and presenting a paper at the Pharmaceutical Market Research Conference 24-25 October in Düsseldorf, GermanyDirector, Anne Cunningham, and Associate Director, Nicky Barclay-Prout, are representing...

Device Attribute Testing

Our client wanted to determine the optimal new blood glucose monitoring device – one that would best retain their current customers and also attract new ones.  They also wanted to...

Research Partnership welcomes 20 new Graduates

This year we are celebrating 20 years in business and as part of our continued growth, we are delighted to announce a new intake of 17 Research Analysts and 3...